






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07D 213/64	A1	(11) International Publication Number: WO 96/39388 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/IB95/00437 (22) International Filing Date: 6 June 1995 (06.06.95) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CHEN, Yuhpyng, L. [US/US]; 8 Waterview Drive, Waterford, CT 06385 (US). RUGGERI, Sally, Gut [US/US]; 53 Twin Lakes Drive, Waterford, CT 06385 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).		(81) Designated States: AU, BR, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.

(54) Title: PROCESS FOR CONVERTING 2,4-DICHLOROPYRIDINES INTO 2-ARYLOXY-4-CHLOROPYRIDINES

## (57) Abstract

This invention relates to a process for converting 2,4-dichloropyridines into 2-aryloxy-4-chloropyridines, comprising reacting a compound of formula (I), wherein R<sup>1</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl; R<sup>2</sup> is methyl or ethyl; and R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are selected, independently, from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy; or a pharmaceutically acceptable salt thereof; comprising reacting a compound of formula (II), wherein R<sup>1</sup> and R<sup>2</sup> are defined as above, with a compound of formula (III), wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are defined as above, in the presence of a base that is capable of deprotonating the compound of formula (III), optionally in the presence of an organometallic halide or oxide and a suitable solvent, and then optionally converting the resulting compound of formula (I) into a pharmaceutically acceptable salt of such compound.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-


5                   PROCESS FOR CONVERTING 2,4-DICHLOROPYRIDINES  
                    INTO 2-ARYLOXY-4-CHLOROPYRIDINES

Background of the Invention

                    This invention relates to a process for converting 2,4-dichloropyridines into 2-aryloxy-4-chloropyridines. This process can be used to prepare 3,6-di-(C<sub>1</sub>-C<sub>4</sub>)alkyl-4-chloro-2-(2,4,6-trisubstitutedphenoxy)pyridines, which are intermediates in the synthesis of pharmaceutically active 2-phenoxy-pyridine derivatives that exhibit activity as corticotropin releasing factor (CRF) antagonists and are useful in the treatment of several neurological disorders. Such pharmaceutically active compounds, methods of preparing them and the neurological disorders that they are useful in treating are described in copending United States Patent Application 08/255,514, which was filed on June 8, 1994. This patent application is incorporated herein by reference in its entirety.

Summary of the Invention

                    This invention relates to a process for preparing a compound of the formula



                    wherein R<sup>1</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl;


                    R<sup>2</sup> is methyl or ethyl; and

                    R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are selected, independently, from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy;  
                    or a pharmaceutically acceptable salt thereof;

35                   comprising reacting a compound of the formula

-2-


5



II

wherein R<sup>1</sup> and R<sup>2</sup> are defined as above, with a compound of the formula

10



III

wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are defined as above, in the presence of a base that is capable of deprotonating the compound of formula III, optionally in the presence of an organometallic halide or oxide and a suitable solvent, and then optionally converting the resulting compound of formula I into a pharmaceutically acceptable salt of such compound.

Suitable bases for this reaction include sodium hydride, potassium hydride, potassium carbonate, cesium carbonate, ammonium hydroxide, n-butyllithium and lithium, sodium or potassium (C<sub>1</sub>-C<sub>4</sub>) alkoxide. Examples of suitable organometallic halides and oxides are copper (I) bromide, iodide or chloride, copper (II) oxide, copper (I) oxide, copper metal and trialkyltin chloride. Examples of suitable solvents are tetrahydrofuran (THF), dimethylsulfoxide (DMSO), acetonitrile, methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>), 1-methyl-2-pyrrolidinone, pyridine, quinoline, N,N-dialkylacetamide, 2,4,6-trimethylpyridine, N,N-dialkylacetamide, N,N-dialkylformamide (e.g. N,N-dimethylformamide), hexamethyl phosphoramide and toluene. The reaction temperature may range from about 0°C to about 180°C and is preferably between about room temperature and about 150°C.

A preferred embodiment of this invention relates to the above process wherein the compound of formula I that is formed is a compound wherein all of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are methyl, the solvent is pyridine, the organometallic halide or oxide is copper (I) iodide and the base is potassium t-butoxide.

Another embodiment of this invention relates to the above depicted reaction of a compound of the formula II with a compound of the formula III, wherein the solvent is selected from dimethylsulfoxide (DMSO), pyridine, 2,4,6-trimethylpyridine, quinoline, and mixtures of the foregoing solvents, the base is selected from potassium hydride, sodium hydride, sodium methoxide, potassium t-butoxide, and sodium t-butoxide, and the organometallic halide or oxide is selected from cuprous bromide, cuprous chloride and cuprous iodide.

Other embodiments of this invention relates to the above depicted reaction of a compound of the formula II with a compound of the formula III, wherein:


- (a) the solvent is pyridine, DMSO or a mixture of pyridine and DMSO; or
- (b) the base is sodium hydride or potassium t-butoxide; or
- (c) the organometallic halide or oxide is cuprous iodide, cuprous bromide or cuprous chloride;
- (d) the solvent is pyridine, R<sup>1</sup> and R<sup>2</sup> in the compound of formula II are both methyl and R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> in the compound of formula III are all methyl;
- (e) the solvent is pyridine, R<sup>1</sup> through R<sup>5</sup> in formulae II and III are all methyl and the base is potassium t-butoxide; or
- (f) the solvent is pyridine, R<sup>1</sup> through R<sup>5</sup> in formulae II and III are all methyl, and the organometallic halide or oxide is cuprous iodide, cuprous bromide or cuprous chloride.

#### Detailed Description of this Invention

Compounds of the formula I are useful as intermediates in the synthesis of 2-phenoxy-pyridine derivatives that are corticotropin releasing factor (CRF) antagonists and are useful in the treatment of disorders for which treatment can be effected or facilitated by antagonizing CRF. Examples of such disorders are those selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV)

infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in mammals, including humans.

The pharmaceutically active CRF antagonists that can be prepared using the intermediates of formula I that are produced by the processes of this invention are depicted below.



In these compounds, B is  $-NR^6R^7$ ,  $-NHCHR^6R^7$ ,  $-OCHR^6R^7$  or  $-SCHR^6R^7$ ;

$R^1$  through  $R^5$  are defined as above;

$R^6$  is  $C_1-C_6$  alkyl which may optionally be substituted with one or two substituents  $R^8$  independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo,  $CF_3$  and  $C_1-C_4$  alkoxy, and wherein said  $C_1-C_6$  alkyl and the  $(C_1-C_4)$ alkyl moiety of said  $C_1-C_4$  alkoxy may optionally contain one carbon-carbon double or triple bond; and

-5-

R<sup>7</sup> is C<sub>1</sub>-C<sub>12</sub> alkyl, aryl or -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R<sup>9</sup> wherein R<sup>9</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and wherein each of the foregoing R<sup>7</sup> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C<sub>1</sub>-C<sub>4</sub> alkyl, or with one substituent selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> alkyl and the C<sub>1</sub>-C<sub>4</sub> alkylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sup>6</sup>R<sup>7</sup> may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom.

The pharmaceutically active compounds depicted above are described in copending United States Patent Application 08/255,514, which was filed on June 8, 1994 and which is incorporated herein by reference in its entirety. Methods of preparing such compounds and their pharmaceutically acceptable salts (hereinafter collectively referred to as "the active agents") are also set forth in that application.

The active agents can be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining compounds of the formula I and pharmaceutically acceptable carriers can be readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex

-6-

silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions containing an active agent in sesame or peanut oil, aqueous propylene glycol or a sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

The effective dosages for the active agents will depend on the intended route of administration and factors such as the age, weight and condition of the patient, as generally known to a physician. The dosage will also depend on the particular illness to be treated. The daily dosage for stress-induced illnesses, inflammatory disorders, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress and drug and alcohol withdrawal symptoms will generally range from about 0.1 to about 50 mg/kg body weight of the patient to be treated.

The following experimental example illustrates the novel process of this invention but does not limit its scope.

#### EXAMPLE 1

##### 4-Chloro-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine

To a 2 liter flask equipped with a mechanical stirrer, a reflux condenser and a nitrogen inlet was charged 250 ml of pyridine. The flask was cooled in an ice bath and charged with 42.5 g (0.312 mmol) of 2,4,6-trimethylphenol and 35.1 g (0.313 mol) of potassium t-butoxide. The flask was warmed to room temperature and charged with 50.0 g (0.284 mol) of 2,4-dichloro-3,6-dimethylpyridine and 13.5 g (0.071 mol) of copper



-7-

(l) iodide. The reaction mixture was heated to reflux for two hours and then cooled to 0°C. The reaction was diluted with 500 ml of hexanes, then mixed with 1000 ml of saturated ammonium chloride ( $\text{NH}_4\text{Cl}$ ). After warming to room temperature, the mixture was stirred overnight. The layers were separated and the organic layer was washed with 3 x 125 ml of 1M ammonium hydroxide ( $\text{NH}_4\text{OH}$ ), 2 x 250 ml of 3N sodium hydroxide ( $\text{NaOH}$ ), 1 x 250 ml of 1N hydrochloric acid ( $\text{HCl}$ ) and 1 x 250 ml of water. After drying over sodium sulfate ( $\text{Na}_2\text{SO}_4$ ), the solids were removed by filtration and washed with hexane. The filtrate was concentrated under vacuum to a brown oil. The residue was mixed with 250 ml methanol and stirred overnight. The resulting slurry was filtered under vacuum. The off-white solids were washed with methanol then dried to obtain 31.6 g (40.4%) of the title compound.


$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.88 (s, 2H), 6.78 (s, 1H), 2.40 (s, 3H), 2.30 (s, 3H), 2.20 (s, 3H), 2.04 (s, 6H) ppm.

The filtrate was concentrated under vacuum to an oil and the residue was mixed with 50 ml of methanol. After stirring overnight, the resulting slurry was cooled to 0°C and filtered under vacuum. The solids were washed with minimal methanol and dried to give an additional 16.1g (20.5%) of material.

-8-

CLAIMS

1. A process for preparing a compound of the formula




wherein R<sup>1</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl;


15 R<sup>2</sup> is methyl or ethyl; and

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are selected, independently, from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy;  
or a pharmaceutically acceptable salt thereof;

comprising reacting a compound of the formula



- 25 wherein R<sup>1</sup> and R<sup>2</sup> are defined as above, with a compound of the formula



wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are defined as above, in the presence of a base that is capable  
of deprotonating the compound of formula III, optionally in the presence of an

organometallic halide or oxide and a suitable solvent, and then optionally converting the resulting compound of formula I into a pharmaceutically acceptable salt of such compound.

2. A process according to claim 1, wherein the base is selected from  
5 sodium hydride, potassium hydride, potassium carbonate, cesium carbonate, ammonium hydroxide, lithium (C<sub>1</sub>-C<sub>4</sub>)alkoxide, sodium or potassium (C<sub>1</sub>-C<sub>4</sub>) alkoxide and n-butyllithium.

3. A process according to claim 1 wherein the organometallic halide or  
oxide is selected from copper (II) oxide, copper (I) oxide, copper metal,  
10 trialkyltinchloride and copper (I) bromide, iodide or chloride.

4. A process according to claim 1 wherein the solvent is selected from  
tetrahydrofuran, dimethylsulfoxide, acetonitrile, methylene chloride, 1-methyl-2-  
pyrrolidinone, pyridine, quinoline, N,N-dialkylacetamide, 2,4,6-trimethylpyridine, N,N-  
dialkylacetamide, N,N-dialkylformamide, hexamethyl phosphoramide, toluene and  
15 mixtures of the foregoing solvents.

5. A process according to claim 1 which produces a compound of the  
formula I wherein all of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are methyl.

6. A process according to claim 1 wherein the solvent is pyridine, quinoline  
or 2,4,6-trimethylpyridine.

7. A process according to claim 5 wherein the solvent is pyridine, quinoline  
20 or 2,4,6-trimethylpyridine.

8. A process according to claim 1 wherein the base is potassium t-butoxide.

9. A process according to claim 5, wherein the base is potassium t-  
butoxide.

10. A process according to claim 1, wherein the organometallic halide or  
25 oxide is copper (I) halide.

11. A process according to claim 5, wherein the organometallic halide or  
oxide is copper (I) halide.

12. A process according to claim 5, wherein the solvent is pyridine, the  
30 organometallic halide or oxide is cuprous iodide and the base is potassium t-butoxide.

13. A process according to claim 1 wherein the solvent is pyridine or DMSO  
or a mixture of pyridine and DMSO.

-10-

14. A process according to claim 1 wherein the base is sodium hydride or potassium t-butoxide.
15. A process according to claim 9 wherein the solvent is pyridine.
16. A process according to claim 15 wherein the organometallic halide or  
5 oxide is a copper (I) halide.

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 95/00437

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D213/64

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,3 637 720 (NISHIYAMA RYUZO ET AL) 25 January 1972	1,2
Y	see the whole document	3-16
Y	EP,A,0 315 916 (SUMITOMO CHEMICAL COMPANY, LIMITED) 17 May 1989 see page 5, line 30 - page 6, line 25; claim 17; examples 8,10	3-16
A	EP,A,0 385 720 (TOSOH CORPORATION) 5 September 1990 see the whole document	1-16
A	WO,A,79 00094 (IMPERIAL CHEMICAL INDUSTRIES LIMITED) 8 March 1979 see page 16 - page 19	1-16

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 December 1995

Date of mailing of the international search report

- 9. 01. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Bosma, P

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: 11 Application No

PCT/IB 95/00437

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US-A-3637720	25-01-72	DE-A-	1770650	11-11-71
		FR-A-	1582125	26-09-69
		GB-A-	1210151	28-10-70
		NL-A-	6808378	16-12-68
-----				
EP-A-315916	17-05-89	DE-D-	3886009	13-01-94
		DE-T-	3886009	14-04-94
		US-A-	5006538	09-04-91
		US-A-	5093373	03-03-92
		JP-A-	2085225	26-03-90
-----				
EP-A-385720	05-09-90	JP-A-	2223556	05-09-90
		JP-A-	3167173	19-07-91
		US-A-	5068336	26-11-91
-----				
WO-A-7900094	08-03-79	AU-B-	584066	18-05-89
		AU-B-	2614984	12-07-84
		AU-B-	572085	05-05-88
		AU-B-	3859678	07-02-80
		CA-C-	1205805	10-06-86
		CA-A-	1142524	08-03-83
		CA-C-	1218065	17-02-87
		CA-A-	1260001	26-09-89
		DE-A-	2862490	21-04-88
		DE-A-	2862491	05-05-88
		DE-A-	2862492	01-09-88
		EP-A, B	0001473	18-04-79
		EP-A, B	0021453	07-01-81
		EP-A, B	0028870	20-05-81
		EP-A, B	0107866	09-05-84
		JP-A-	1025760	27-01-89
		JP-C-	1848954	07-06-94
		JP-A-	1063572	09-03-89
		JP-C-	1848955	07-06-94
		JP-C-	1662890	19-05-92
		JP-B-	2045626	11-10-90
		JP-A-	54032479	09-03-79
		OA-A-	6075	30-06-81
		SI-A-	7811927	31-12-94
		US-A-	4317913	02-03-82

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 95/00437

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-7900094		US-A- 4324627	13-04-82
		US-A- 4508907	02-04-85
		US-A- 4555575	26-11-85
		US-A- 4925947	15-05-90
		GB-A- 2002368	21-02-79
		JP-C- 1764880	11-06-93
		JP-B- 4033788	04-06-92
		JP-A- 62116562	28-05-87
		JP-A- 62111968	22-05-87
-----			